Suhail Mufti - Scandinavian ChemoTech Local Director
CMOTEC-B | SEK 1.74 0.04 2.35% |
Insider
Suhail Mufti is Local Director of Scandinavian ChemoTech AB
Age | 49 |
Phone | 46 1 0218 9300 |
Web | https://chemotech.se |
Scandinavian ChemoTech Management Efficiency
The company has return on total asset (ROA) of (0.5117) % which means that it has lost $0.5117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1711) %, meaning that it generated substantial loss on money invested by shareholders. Scandinavian ChemoTech's management efficiency ratios could be used to measure how well Scandinavian ChemoTech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Johanna Christensen | Cantargia AB | N/A | |
Susanne Lagerlund | Cantargia AB | N/A | |
Kicki Johansson | Vicore Pharma Holding | 65 | |
Mats Rnngard | Enorama Pharma AB | 67 | |
Kristina Torfgard | Alzinova AB | N/A | |
Peter Madsen | Cantargia AB | N/A | |
Hans Jeppsson | Vicore Pharma Holding | N/A | |
Adnan Deronic | Cantargia AB | N/A | |
Per Norlen | Xintela AB | 53 | |
Hakan Skogstrom | Alzinova AB | 62 | |
Anders Bylock | Alzinova AB | N/A | |
Ignacio GarciaRibas | Cantargia AB | N/A | |
Anders Sandberg | Alzinova AB | 51 | |
Kjell Sjstrm | Cantargia AB | N/A | |
Johanna Grans | Vicore Pharma Holding | N/A | |
Johan Raud | Vicore Pharma Holding | N/A | |
Nina Valkama | Cantargia AB | N/A | |
CarlJohan MD | Vicore Pharma Holding | 67 | |
Marcuss | Cantargia AB | N/A | |
Nina Carlen | Vicore Pharma Holding | N/A | |
Jessica Shull | Vicore Pharma Holding | N/A |
Management Performance
Return On Equity | -1.17 | |||
Return On Asset | -0.51 |
Scandinavian ChemoTech Leadership Team
Elected by the shareholders, the Scandinavian ChemoTech's board of directors comprises two types of representatives: Scandinavian ChemoTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scandinavian. The board's role is to monitor Scandinavian ChemoTech's management team and ensure that shareholders' interests are well served. Scandinavian ChemoTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scandinavian ChemoTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stefan Frick, CEO Founder | ||
Jonathan Furelid, Head relation | ||
Prabhat Rastogi, Chief India | ||
Ann Ohlsson, Head Fin | ||
Suhail Mufti, Local Director |
Scandinavian Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scandinavian ChemoTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.17 | |||
Return On Asset | -0.51 | |||
Operating Margin | (48.69) % | |||
Current Valuation | 68.38 M | |||
Shares Outstanding | 10.64 M | |||
Shares Owned By Insiders | 26.03 % | |||
Shares Owned By Institutions | 3.32 % | |||
Price To Book | 8.87 X | |||
Price To Sales | 159.69 X | |||
Revenue | 49 K |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Scandinavian Stock
Scandinavian ChemoTech financial ratios help investors to determine whether Scandinavian Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Scandinavian with respect to the benefits of owning Scandinavian ChemoTech security.